The CD40L program commenced in 2006 with a $2.27mil Govt grant. Hits were found and in-vitro studies were done during 2007 and 2008.
By the end of 2009, they had three leads that were undergoing in-vivo testing. To extend half-life in the bloodstream, PEGylation was used. Also used was a high affinity binder to serum albumin developed by a Swedish company, Affibody. At this time they entered into an agreement with US-based Aegis, to evaluate their technology that delivers peptides by the inhaled route.
In 2010 PYC screened their 'next generation' of libraries which yielded hits more potent in-vitro, than the original candidates.
In 2011 these leads were enhanced using Pepscan's CLIPs chemistry which staples or constrains peptides. It was claimed this improved in-vitro potency.
In 2012 in-house structural modelling was being used on the peptides to optimise activity.
Now in 2013 the peptides are being tested in-vivo and PYC are building a 'data package' that includes benchmarks required by prospective clients. .............
Seven years to get to these latest in-vivo studies.
Does that sound like a lean mean Biotech company beating rivals to the pharma deal??
PYC Price at posting:
2.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)